Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
10.03. | Sun Pharma buys Checkpoint and its new cancer drug | ||
07.03. | Neurotech's cell therapy gets FDA nod for eye disorder MacTel | ||
07.03. | One of J&J's blockbuster depression hopes has flamed out | ||
07.03. | Denali's ALS programme suffers another setback | ||
07.03. | Biogen, Apple study finds smart devices can track cognition | ||
06.03. | FDA Commissioner pick Makary pressed by Senators on vaccines | ||
06.03. | Digital health firm XRHealth hits the M&A trial again | ||
06.03. | Trump's NIH pick closer to role as court blocks budget cuts | ||
06.03. | NICE agrees to look again at Alzheimer's drug Leqembi | ||
06.03. | Second senior NHS England executive heads for the exit | ||
06.03. | Novo Nordisk follows Lilly into DTC obesity drug market | ||
05.03. | Jazz swings further into cancer with Chimerix takeover | ||
05.03. | FDA starts review of Roche's Gazyva in lupus nephritis | ||
05.03. | Lawrence Tallon will lead MHRA after June Raine retires | ||
05.03. | Bayer CEO warns of tough 2025 as turnaround plan beds in | ||
05.03. | FDA approves first generics of anticoagulant Xarelto | ||
04.03. | Enhertu extends survival in advanced gastric cancer | ||
04.03. | Sofinnova raises €1.2bn to back 'up to 60' companies | ||
04.03. | Roche ends the 30-year US hiatus in new stroke drugs | ||
04.03. | Pharma urges NHS to put medicines at heart of 10-year plan | ||
04.03. | Lilly uses Oscars ad to warn about 'untested' GLP-1s | ||
03.03. | Takeda scores with polycythemia vera drug in phase 3 trial | ||
03.03. | Australia stands firm on 'no' to Alzheimer's drug Leqembi | ||
03.03. | GSK bows to Trump pressure and pauses diversity policies | ||
03.03. | UK haemophilia A patients get once-weekly treatment option |